Publications by authors named "T Oikonomou"
Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study.
BMC Gastroenterol
April 2024
Background: Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive method to assess liver fibrosis in patients with CHB. Our aim was to explore factors that may affect changes in LSMs during long term tenofovir (TDF) monotherapy in a well characterized cohort of patients with compensated CHB.
View Article and Find Full Text PDFBackground: The use of nucleos(t)ide analogs (NAs) with a high genetic barrier to resistance, namely entecavir and tenofovir, has improved the efficacy of antiviral prophylaxis against hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, the optimal duration and dosage of hepatitis B immunoglobulin (HBIG) administration, particularly in patients transplanted for HBV and hepatitis D virus (HDV) coinfection, remains controversial.
Methods: We evaluated 28 patients transplanted for HBV/HDV cirrhosis.
Article Synopsis
- The study examined the significance of platelet (PLT)-based biomarkers in predicting outcomes for 525 patients with stable decompensated cirrhosis, focusing on variables like mean PLT volume and various PLT-based scores.
- Results indicated that the aspartate aminotransferase-to-PLT ratio index (APRI) strongly correlated with survival outcomes, more so than traditional scoring systems like MELD and CTP.
- The findings suggest that APRI could serve as an effective noninvasive predictor for patient prognosis in decompensated cirrhosis, offering a new approach to assess liver disease severity.*
Background & Aims: Tenofovir alafenamide fumarate (TAF) was shown equally efficacious in suppressing hepatitis B virus (HBV) but with less renal toxicity than tenofovir disoproxil fumarate (TDF). The aim of this real-world study was to evaluate renal function in post-liver transplantation (LT) patients that changed TDF with TAF.
Methods: The TAF group (n=17) included patients who switched to TAF due to low (<60 ml/min/1.
Background: Galectin-3 (gal-3) has been proposed as a marker of established renal impairment, with predictive value in stable decompensated cirrhosis.
Methods: 150 stable decompensated patients were assessed in 2 transplant centers. Patients' renal function was assessed using Chromium-EDTA ("true" glomerular filtration rate).